• The potentially clinically relevant differences in stroke when using apixaban or rivaroxaban in patients with BMI
    ≥50 kg/m2 compared with that in patients with BMI <30 kg/m2 did not reach statistical significance; however, this
    study was underpowered
  • Additional studies are needed to confirm these findings
  • This study contributes to the growing body of evidence that apixaban and rivaroxaban may be effective and safe
    to use for NVAF in patients with severe obesity and BMI ≥50 kg/m2